SO010/#1243 Risks and benefits of a national adoption of sentinel node mapping in low and intermediate risk endometrial cancer -the sentirec-endo study
DOI:
10.1136/ijgc-2023-igcs.24
Publication Date:
2023-11-08T07:00:51Z
AUTHORS (12)
ABSTRACT
<h3>Introduction</h3> Surgical staging of endometrial cancer (EC) serves to allocate women with lymph node metastases adjuvant treatment. Sentinel (SLN) mapping can accurately detect in EC low- or intermediate-risk (LR IR) metastases. We aim investigate risks and benefits a national protocolled adoption SLN LR IR EC, real-life clinical setting. <h3>Methods</h3> A multicenter prospective study SLN-mapping from March 2017-February 2022. Postoperative complications were classified according Clavien-Dindo. Lymphoedema was evaluated by validated patient-reported outcome measures at baseline three months postoperatively. <h3>Results</h3> 627 included the analyses, 458 LR- 169 EC. The detection rate 94.3% (591/627). overall incidence 9.3% (58/627), 4.4% (20/458) 22.5% (38/169) group. Only 0.3% (2/627) experienced an intraoperative complication associated procedure. postoperative 8% (50/627). mean difference score lymphoedema below threshold for importance 4.3/100 (95%CI 2.6–5.9). leg swelling heaviness low, 5.2% 6.1%, respectively. <h3>Conclusion/Implications</h3> is safe procedure IR, carrying very low risk early lymphoedema, perioperative- complications. change practice contributed improved treatment allocation both groups thus supports further international implementation.
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (0)
CITATIONS (0)
EXTERNAL LINKS
PlumX Metrics
RECOMMENDATIONS
FAIR ASSESSMENT
Coming soon ....
JUPYTER LAB
Coming soon ....